Schistosoma mansoni thioredoxin-glutathione reductase (SmTGR)

Schistosoma mansoni thioredoxin-glutathione reductase (SmTGR) is a unique and essential multifunctional flavoenzyme that serves as the primary regulator of redox homeostasis in the parasitic flatworm responsible for schistosomiasis. Unlike mammalian hosts, which utilize separate enzymes for the thioredoxin and glutathione pathways, Schistosoma mansoni relies entirely on SmTGR to reduce both thioredoxin and glutathione disulfide. This dependency creates a metabolic bottleneck, making the enzyme a high-priority therapeutic target for the development of antischistosomal agents. The enzyme's structure includes a specialized selenocysteine-containing C-terminal tail that is critical for its catalytic activity and broad substrate specificity. Drugs like auranofin, originally used for rheumatoid arthritis, have been identified as potent inhibitors of SmTGR, demonstrating the ability to kill adult, juvenile, and larval stages of the parasite by inducing severe oxidative stress. Because SmTGR is functionally distinct from the separate redox enzymes found in humans, it offers a pathway for selective drug development aimed at treating the over 200 million people affected by schistosomiasis worldwide.

Other names

Thioredoxin-glutathione reductaseTGRThioredoxin/glutathione reductaseSelenocysteine-containing oxidoreductaseMultifunctional oxidoreductase TGR

Drugs targeting SmTGR typically act as irreversible or noncompetitive inhibitors that bind to the enzyme's active site, often targeting the essential selenocysteine residue. Inhibition of SmTGR leads to the depletion of reduced thioredoxin and glutathione, causing a catastrophic failure of the parasite's redox homeostasis and subsequent death due to host-induced oxidative damage.